The CDC has provided interim recommendations for the vaccination and treatment of HIV-infected adults and adolescents affected by 2009 H1N1 influenza. HIV-infected patients between the ages of 25–64 years, as well as all persons 6 months to 24 years of age are initial target groups for the 2009 H1N1 influenza vaccine and should be vaccinated. Recommendations for treatment and chemoprophylaxis of 2009 H1N1 influenza in HIV-infected patients are the same used for others at higher risk of complications from seasonal influenza.

Antiviral treatment and chemoprophylaxis dosing regimens recommended for adults with HIV-infection are the same as those for adults who have seasonal influenza. Relenza (zanamivir, from GlaxoSmithKline) or Tamiflu (oseltamivir, from Roche) should be initiated as soon as possible after the onset of influenza symptoms, with benefits expected to be greatest if started within 48 hours of onset. Healthcare providers should initiate empiric antiviral treatment as soon as possible; waiting for laboratory confirmation of influenza to begin treatment is not necessary.

Recommendations for the use of influenza antivirals for HIV-infected adults and adolescents might change as additional data on the benefits and risks of antiviral therapy in such persons become available.

For more information visit